Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno & Daisuke Nitta. (2022) Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study. Expert Opinion on Drug Safety 21:11, pages 1411-1422.
Read now
Read now
Konstantinos P. Imprialos, Konstantinos Stavropoulos, Michael Doumas, Asterios Karagiannis & Vasilios G. Athyros. (2017) The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology 10:11, pages 1251-1261.
Read now
Read now
Jayant Dey. (2017) SGLT2 inhibitor/DPP-4 inhibitor combination therapy – complementary mechanisms of action for management of type 2 diabetes mellitus. Postgraduate Medicine 129:4, pages 409-420.
Read now
Read now
André J. Scheen. (2015) SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment. Expert Opinion on Drug Safety 14:12, pages 1879-1904.
Read now
Read now
André J Scheen. (2014) Evaluating SGLT2 inhibitors for type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opinion on Drug Metabolism & Toxicology 10:5, pages 647-663.
Read now
Read now
Articles from other publishers (26)
T. S. Panevin, M. S. Eliseev, A. O. Bobkova, A. E. Dimitreva & M. M. Urumova. (2023) The use of dapaglifl ozin in a comorbid patient: new perspectives. Nephrology (Saint-Petersburg) 27:2, pages 109-115.
Crossref
Crossref
Youn Huh & Young Sik Kim. (2022) Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. BMC Primary Care 23:1.
Crossref
Crossref
T. S. Panevin, M. S. Eliseev, M. V. Shestakova & E. L. Nasonov. (2020) Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout. Terapevticheskii arkhiv 92:5, pages 110-118.
Crossref
Crossref
Konstantinos Imprialos, Konstantinos Stavropoulos & Vasilios Papademetriou. (2019) Sodium-Glucose Cotransporter-2 Inhibitors, Reverse J-Curve Pattern, and Mortality in Heart Failure. Heart Failure Clinics 15:4, pages 519-530.
Crossref
Crossref
Ze Chen & Gerui Li. (2019) Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation 39:6, pages 521-531.
Crossref
Crossref
Francisco J. Tinahones, Baptist Gallwitz, Matias Nordaby, Sophia Götz, Mario Maldonado-Lutomirsky, Hans J. Woerle & Uli C. Broedl. (2017) Linagliptin as add-on to empagliflozin and metformin in patients with type 2 diabetes: Two 24-week randomized, double-blind, double-dummy, parallel-group trials. Diabetes, Obesity and Metabolism 19:2, pages 266-274.
Crossref
Crossref
Samy Hadjadj, Julio Rosenstock, Thomas Meinicke, Hans J. Woerle & Uli C. Broedl. (2016) Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes. Diabetes Care 39:10, pages 1718-1728.
Crossref
Crossref
Kun-Ho Yoon, Rimei Nishimura, Jisoo Lee, Susanne Crowe, Afshin Salsali, Thomas Hach & Hans J. Woerle. (2016) Efficacy and safety of empagliflozin in patients with type 2 diabetes from Asian countries: pooled data from four phase III trials. Diabetes, Obesity and Metabolism 18:10, pages 1045-1049.
Crossref
Crossref
Xueying Tan & Jingbo Hu. (2016) Empagliflozin/Linagliptin: Combination therapy in patients with type 2 diabetes. Annales d'Endocrinologie 77:5, pages 557-562.
Crossref
Crossref
André J. Scheen. (2016) SGLT2 Inhibitors: Benefit/Risk Balance. Current Diabetes Reports 16:10.
Crossref
Crossref
Aki Okamoto, Hirohide Yokokawa, Hironobu Sanada & Toshio Naito. (2016) Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients. Drugs in R&D 16:3, pages 255-261.
Crossref
Crossref
Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D. Müller & Richard D. DiMarchi. (2016) Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metabolism 24:1, pages 51-62.
Crossref
Crossref
Sho-ichi YamagishiTakanori Matsui. (2016) Protective Role of Sodium–Glucose Co-Transporter 2 Inhibition Against Vascular Complications in Diabetes. Rejuvenation Research 19:2, pages 107-114.
Crossref
Crossref
Serena Tonstad, Stephan Rössner, Aila Rissanen & Arne Astrup. (2016) Medical management of obesity in Scandinavia 2016. Obesity Medicine 1, pages 38-44.
Crossref
Crossref
Rachel M. Saroka, Michael P. Kane, Robert S. Busch, Jay. Watsky & Robert A. Hamilton. (2015) SGLT-2 Inhibitor Therapy Added to GLP-1 Agonist Therapy in the Management of T2DM. Endocrine Practice 21:12, pages 1315-1322.
Crossref
Crossref
Xiang-Yang Liu, Ning Zhang, Rui Chen, Jia-Guo Zhao & Pei Yu. (2015) Efficacy and safety of sodium–glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2 years. Journal of Diabetes and its Complications 29:8, pages 1295-1303.
Crossref
Crossref
Andrew Lewin, Ralph A. DeFronzo, Sanjay PatelDacheng Liu, Renee Kaste, Hans J. Woerle & Uli C. Broedl. (2015) Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes. Diabetes Care 38:3, pages 394-402.
Crossref
Crossref
Ralph A. DeFronzo, Andrew Lewin, Sanjay PatelDacheng Liu, Renee Kaste, Hans J. Woerle & Uli C. Broedl. (2015) Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin. Diabetes Care 38:3, pages 384-393.
Crossref
Crossref
Karel Kostev, Juliana Rex, Timo Rockel & Christina Heilmaier. (2015) Effects of selected antidiabetics on weight loss – A retrospective database analysis. Primary Care Diabetes 9:1, pages 74-77.
Crossref
Crossref
André J. Scheen. (2014) Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus. Drugs 75:1, pages 33-59.
Crossref
Crossref
A.J. Scheen & N. Paquot. (2014) Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence. Diabetes & Metabolism 40:6, pages S4-S11.
Crossref
Crossref
Greg L. Plosker. (2014) Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes. Drugs 74:18, pages 2191-2209.
Crossref
Crossref
André J Scheen & Luc F Van Gaal. (2014) Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. The Lancet Diabetes & Endocrinology 2:11, pages 911-922.
Crossref
Crossref
Martin Ridderstråle, Knut Robert Andersen, Cordula Zeller, Gabriel Kim, Hans J Woerle & Uli C Broedl. (2014) Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. The Lancet Diabetes & Endocrinology 2:9, pages 691-700.
Crossref
Crossref
Menghan Liu, Magdalene K. Montgomery, Corrine E. Fiveash, Brenna Osborne, Gregory J. Cooney, Kim Bell-Anderson & Nigel Turner. (2014) PPARα-independent actions of omega-3 PUFAs contribute to their beneficial effects on adiposity and glucose homeostasis. Scientific Reports 4:1.
Crossref
Crossref
Greg L. Plosker. (2014) Canagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus. Drugs 74:7, pages 807-824.
Crossref
Crossref